Sandra Ann Springer, MD
Research & Publications
Biography
News
Locations
Research Summary
Dr. Springer's has significant clinical research experience with integrating addiction medicine and infectious disease prevention and treatment interventions. She is the Director of InSTRIDE –Integrating Substance Use Treatment Research with Infectious Disease for Everyone https://medicine.yale.edu/lab/springer/ In particular, she has focused on evaluating medication treatments for opioid and alcohol use disorders to improve HIV treatment outcomes among persons with HIV (PWH) released from prison and jail. She currently has an Avant Garde Award (DP1) from NIDA to improve ending the HIV epidemic among persons who use drugs (PWUD) through providing HIV prevention (PrEP) and treatment (antiretroviral therapy) integrated with treatment of substance use disorders through mobile health units with pharmacists providing medication treatment directly to people in need combined with community health care workers and telehealth clinicians. In addition to being a Principal Investigator (PI) on this newly funded Avant Garde Award, she is currently PI on 6 grants: (1) a 5 year R01 from NIDA evaluating the impact of medication treatment for opioid use disorder (MOUD) on immunologic outcomes among persons with opioid use disorder (OUD) living with HIV and without HIV infection with colleague Dr. Albert Shaw; (2) a PI on a NIDA funded R33/R61that is evaluating the impact of all forms of MOUD on HIV persistence with colleagues at Yale , Drs. Ya-Chi Ho and Yuval Kluger; (3) the contact PI of a multisite NCATS U01 that is evaluating the integration of infectious disease treatment and OUD treatment with injectable buprenorphine in hospitalized patients with OUD with co-PIs Dr. Edward Nunes, Frances Levin and Kathleen Brady; (4) a co-PI for a VA COOP comparative effectiveness RCT of injectable and sublingual buprenorphine among 900 Veterans with OUD across 20 VA national sites with co-PI Dr. Ismene Petrakis; (5) an MPI on a NIDA JCOIN HEALing award performing a 5 multisite RCT comparing long acting buprenorphine to XR-NTX for persons in prison and jail with OUD with MPIs Dr. Joshua Lee (contact), Lisa Marsch, Robert Schwartz, Elizabeth Waddell and David Farabee; (6) contact PI of a NIDA JCOIN HEALing award that is a hybrid type 1 implementation effectiveness RCT comparing mobile health unit and patient navigation community linkage programs to improve OUD and HIV prevention (PrEP) and treatment (ART) services for persons in prison and jail with co-PIs Drs. Kevin Knight and Ank Nijhawan. She also is developing a drop in clinic at 135 college street for persons who are in need of care for substance use , HIV prevention and treatment as well as HCV treatment and other needs along with her Mobile health unit that is in addition to providing research also providing clinical care to persons in Tolland, Windham, Middlesex, Hartford and New Haven Counties.
Specialized Terms: HIV, HIV prevention, Pre-exposure prophylaxis, PrEP, Opioid use disorder, Medication treatment for Opioid use disorder, buprenorphine, extended-release naltrexone, criminal justice involved persons, persons who use drugs (PWUD), Veterans, prisons, jails.
Extensive Research Description
I am fortunate to have had considerable success as an independent investigator starting with early research experiences as an undergraduate at Harvard1-3and during my training as an Infectious Disease Fellow. I have focused my entire research career on developing and evaluating interventions for persons affected by substance use disorders and related infectious diseases, in particular those living with or at risk for HIV; and I have been continuously NIH funded since my NIDA K23 award in 2005. I am considered one of the leaders in clinical research at the intersection ID/HIV and substance use disorders. My work in particular has specifically addressed two intersecting epidemics in this country: the opioid epidemic and the HIV epidemic. My research has shown that medication treatment of opioid use disorder, as well as alcohol use disorder, in persons with HIV improves HIV viral suppression as well as substance use outcomes. This is in line with the goals of the United States Ending the HIV Epidemic (EHE) plan to reduce new HIV infections by 90% by 20304. Most importantly, I have shown that in order to achieve these goals; we must integrate treatment of opioid use disorder (OUD) with medication treatment of OUD (MOUD) (e.g. buprenorphine, methadone, extended-release naltrexone (XR-NTX)) with HIV treatment and prevention services.
During my ID fellowship at Yale, my research identified that persons with HIV who are incarcerated lose viral suppression (VS) within 3 months after release5,6and surmised that relapse to substance use interfered with the HIV care cascade7,8. During my NIDA K23 award that launched my research career I developed the first protocol to use buprenorphine (BPN) as relapse prevention for persons with OUD and HIV transitioning to the community from prison and jail. This pilot study confirmed that BPN was not only well-accepted and tolerated, but it decreased relapse to opioid use and improved HIV VS 6 months after release.9,10 I also evaluated the impact of depression on HIV antiretroviral therapy (ART) adherence among released prisoners with HIV transitioning to the community.11In addition during this time I also created rapid OUD diagnostic tool for non-clinicians called the Rapid Opioid Dependency Screen (RODS)12 that is freely available and is being used by multiple clinical and justice settings to aid in diagnosing OUD. This early body of innovative work was the foundation of my career of continued innovations in integration of treatment of OUD and ID/HIV. After that early BPN pilot project I was awarded two R01s (NIAAA and NIDA) back to back that evaluated the effect of a monthly injectable medication treatment, XR-NTX, in the only ever double blind placebo controlled trials among PWH with AUD and OUD respectively, and both found that XR-NTX achieved and maintained HIV VS 6 months after release from prison and jail.13-18 Further our recent systematic review and meta-analysis of published studies of MOUD on infectious disease outcomes that we just completed also showed that MOUD improves VS19. These innovative studies established that medication treatment of the OUD (and AUD) combined with HIV treatment leads to HIV VS, the goal of treatment of HIV and public health, as it is TREATMENT AS PREVENTION20. Persons living with HIV cannot transmit HIV to uninfected persons if they have VS, thus incorporating MOUD is essential to the goals of the EHE plan.
This early work then led to ground-breaking new collaborations including those within and outside of my discipline to advance further innovative research including: with addiction psychiatrists like Drs. Ned Nunes, Frances Levin & Kathleen Brady on a current innovative research study integrating MOUD into hospital settings in those with concurrent infections related to OUD using long-acting injectable buprenorphine where I am contact PI (NCATS U01TR002763)21; with Dr. Ismene Petrakis at the Veterans Administration in CT where we are co-PIs on the first VA National 20 multisite study comparing two forms of buprenorphine (monthly injectable and daily sublingual) in 900 Veterans with OUD (VA CSP#2014); with basic science researchers evaluating how MOUD affects inflammation and HIV latency with innovative NIH awards as contact PI collaborating with Drs. Albert Shaw (NIDA R01DA043337)22and Ya-Chi Ho & Yuval Kluger (NIDA R61/R33 DA047037)); with implementation scientists (Dr. Nabila El-Bassel) through work on the NY state HEALing communities award (UM1DA049415); with implementation researcher Dr. Kevin Knight and ID specialist Ank Nijhawan on our $11.5 million NIDA U01DA053039 (new JCOIN hub) where I am contact PI, to compare mobile health unit provision of services to patient navigator services for persons who use drugs released from justice settings to link to PrEP/ART and MOUD23, that is also harmonizing with all of JCOIN hubs and HPTN 094 (Steve Shoptaw & Nabila El-Bassel, PIs); with technology researchers working at the interface of OUD like Dr. Sean Young; with public health expert Gregg Gonsalves where we are evaluating the effect of MOUD on VS in Veterans with HIV and OUD; and with addiction medicine specialists like Josh Lee where we are MPIs with Liz Waddell, Robert Schwartz, David Farabee, & Lisa Marsch on a NIDA JCOIN funded RCT (U01DA047982)24comparing injectable buprenorphine to injectable naltrexone in persons in prison and jail. I currently have also received a prestigious Avant Garde Award (DP1) from NIDA for 5 years as of June 2022 that is evaluating a new model of care to provide HIV prevention and treatment integrated with treatment of opioid use disorder through a mobile hub and spokes model to bring prevention and treatment services to people who use drugs wherever they live including those who are unhoused; collaborating with pharmacists, telehealth clinicians and community health workers to help End HIV and overdose epidemics in this country. Through work collaborating with others in research, clinical work and on national committees, I have been able to more broadly discuss the importance of integration of HIV and addiction prevention and treatment services and translate science into action with policy briefs and changes in national guidelines also.25-30
References:
1. Springer SA, Gastfriend DR. A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. J Addict Dis. 1995;14(2):53-66.
2. Levin JM, Holman BL, Mendelson JH, et al. Gender differences in cerebral perfusion in cocaine abuse: technetium-99m-HMPAO SPECT study of drug-abusing women. J Nucl Med. 1994;35(12):1902-1909.
3. Teoh SK, Sarnyai Z, Mendelson JH, et al. Cocaine effects on pulsatile secretion of ACTH in men. J Pharmacol Exp Ther. 1994;270(3):1134-1138.
4. Ending the HIV Epidemic : A Plan For America. 2019. https://www.cdc.gov/endhiv/index.html
. Accessed April 10, 2020.
5. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754-1760.
6. Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2007;8(4):205-212.
7. Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;53(5):469-479.
8. Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American journal of drug and alcohol abuse. 2011;37(1):12-21.
9. Springer S, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes For Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment Journal of Urban Health. 2010.
10. Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS ONE. 2012;7(5):e38335.
11. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009;21(8):976-983.
12. Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). J Correct Health Care. 2015;21(1):12-26.
13. Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial. J Acquir Immune Defic Syndr. 2018;79(1):92-100.
14. Springer SA, Di Paola A, Azar MM, et al. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. J Acquir Immune Defic Syndr. 2018;78(1):43-53.
15. Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39(2):256-268.
16. Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37(2):209-218.
17. Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158-165.
18. Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158-170.
19. McNamara K, Biondi BE, Hernandez-Ramirez RU, Taweh N, Grimshaw AA, Springer SA. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes. Open Forum Infect Dis. 2021.
20. Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. J Acquir Immune Defic Syndr. 2015;69 Suppl 1:S155-S161.
21. Seval N, Frank C, Litwin AH, et al. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemp Clin Trials. 2021;Jun(105).
22. Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemp Clin Trials Commun. 2021;Jan 6(21).
23. Taweh N, Schlossberg E, Frank C, et al. Linking Criminal Justice-Involved Individuals to HIV, Hepatitis C, and Opioid Use Disorder Prevention and Treatment Services Upon Release to the Community: Progress, Gaps, and Future Directions. International Journal of Drug Policy. 2021.
24. Waddell EN, Springer SA, Marsch L, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abuse Treat. 2021;Apr 8.
25. Springer SA, Korthuis PT, Del Rio C. Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Ann Intern Med. 2018;169(5):335-336.
26. Springer SA, Merluzzi AP, Del Rio C. Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics: A Report From the National Academies of Sciences, Engineering, and Medicine. JAMA.2020.
27. Seval N, Eaton E, Springer SA. Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. Open Forum Infect Dis. 2020;7(1):ofz539.
28. Springer SA, Barocas JA, Wurcel A, et al. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda. Journal of Infectious Diseases. 2020;222(Suppl 5):S230-238.
29. Springer SA, Biondi BE, Frank C, El-Bassel N. A Call to Action to Combat the Opioid Epidemic among Women. J Addict Med. 2020.
30. Serota DP, Barocas JA, Springer SA. Infectious complications of addiction: A call for a new subspecialty within infectious diseases. Cain Infect Dis. 2019.
Coauthors
Research Interests
Acquired Immunodeficiency Syndrome; Alcoholism; Buprenorphine; Community Health Workers; HIV; Mobile Health Units; Naltrexone; Opioid-Related Disorders; Prisoners; Risk-Taking; Randomized Controlled Trial; Substance-Related Disorders; Patient Navigation; Pre-Exposure Prophylaxis; Addiction Medicine
Public Health Interests
Behavioral Health; Clinical Trials; HIV/AIDS; Infectious Diseases; Substance Use, Addiction; Pharmaceuticals and Medical Devices
Selected Publications
- Integrated Care Models: HIV and Substance UseHill K, Kuo I, Shenoi S, Desruisseaux M, Springer S. Integrated Care Models: HIV and Substance Use. Current HIV/AIDS Reports 2023, 1-10. PMID: 37698755, DOI: 10.1007/s11904-023-00667-9.
- Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐CliniciansDi Paola A, Farabee D, Springer S. Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians. Psychiatric Research And Clinical Practice 2023, 5: 78-83. PMID: 37711754, PMCID: PMC10499189, DOI: 10.1176/appi.prcp.20230022.
- Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]Lier A, Seval N, Vander Wyk B, Di Paola A, Springer S. Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]. Journal Of Substance Abuse Treatment 2023, 150: 209074. PMID: 37271717, DOI: 10.1016/j.josat.2023.209074.
- The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIVParchinski K, Di Paola A, Wilson A, Springer S. The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. Drug And Alcohol Dependence Reports 2023, 7: 100159. PMID: 37159815, PMCID: PMC10163604, DOI: 10.1016/j.dadr.2023.100159.
- Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They AreSpringer S. Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are. Journal Of General Internal Medicine 2023, 38: 2816-2818. PMID: 37002460, PMCID: PMC10506995, DOI: 10.1007/s11606-023-08142-2.
- Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical TrialSeval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 36701748, PMCID: PMC10368784, DOI: 10.1097/adm.0000000000001136.
- Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.Seval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 37579095, DOI: 10.1097/adm.0000000000001136.
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsGandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, Lehmann C, Springer S, Sax P, Thompson M, Benson C, Buchbinder S, del Rio C, Eron J, Günthard H, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329: 63-84. PMID: 36454551, DOI: 10.1001/jama.2022.22246.
- The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional studySaunders E, Satcher M, Monico L, McDonald R, Springer S, Farabee D, Gryczynski J, Nyaku A, Reeves D, Kunkel L, Schultheis A, Schwartz R, Lee J, Marsch L, Waddell E. The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study. Health & Justice 2022, 10: 35. PMID: 36529829, PMCID: PMC9760540, DOI: 10.1186/s40352-022-00199-1.
- Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use DisorderLier A, Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022 DOI: 10.1093/ofid/ofac624.
- Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use DisorderLier A, Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.
- Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorderLier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. Journal Of Substance Abuse Treatment 2022, 142: 108852. PMID: 35988513, PMCID: PMC9509444, DOI: 10.1016/j.jsat.2022.108852.
- Gender differences among persons entering medication treatment for opioid use disorder in the communityDi Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.
- Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved personsSpringer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.
- Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the communityBiondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.
- Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veteransPetrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.
- Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South AfricaGrammatico MA, Moll AP, Choi K, Springer SA, Shenoi SV. Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa. Journal Of The International AIDS Society 2021, 24: e25848. PMID: 34826363, PMCID: PMC8625837, DOI: 10.1002/jia2.25848.
- Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistenceSchultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.
- Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohortFredericksen RJ, Whitney BM, Trejo E, Nance RM, Fitzsimmons E, Altice FL, Carrico AW, Cleland CM, Del Rio C, Duerr A, El-Sadr WM, Kahana S, Kuo I, Mayer K, Mehta S, Ouellet LJ, Quan VM, Rich J, Seal DW, Springer S, Taxman F, Wechsberg W, Crane HM, Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort. BMC Public Health 2021, 21: 2002. PMID: 34736425, PMCID: PMC8567631, DOI: 10.1186/s12889-021-12026-7.
- Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatmentBiondi BE, Frank CA, Forray A, Springer SA. Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment. Substance Abuse 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.
- Commentary on Murphy et al.: What will it take to prescribe extended‐release naltrexone to treat alcohol use disorder?Springer SA. Commentary on Murphy et al.: What will it take to prescribe extended‐release naltrexone to treat alcohol use disorder? Addiction 2021, 117: 282-283. PMID: 34549844, DOI: 10.1111/add.15668.
- A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease OutcomesMcNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, Springer SA. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes. Open Forum Infectious Diseases 2021, 8: ofab289-. PMID: 34430670, PMCID: PMC8378589, DOI: 10.1093/ofid/ofab289.
- Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directionsTaweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, Springer SA. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. International Journal Of Drug Policy 2021, 96: 103283. PMID: 34020864, PMCID: PMC8568621, DOI: 10.1016/j.drugpo.2021.103283.
- Hepatitis C in the United States: One Step Forward, Two Steps Back.Rio CD, Springer SA. Hepatitis C in the United States: One Step Forward, Two Steps Back. American Journal Of Public Health 2021, 111: 768-769. PMID: 33826392, PMCID: PMC8033994, DOI: 10.2105/ajph.2021.306251.
- Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Abuse Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.
- Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorderSeval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, Springer SA. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemporary Clinical Trials 2021, 105: 106394. PMID: 33838307, PMCID: PMC8172465, DOI: 10.1016/j.cct.2021.106394.
- Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorderBiondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemporary Clinical Trials Communications 2021, 21: 100704. PMID: 33490708, PMCID: PMC7807244, DOI: 10.1016/j.conctc.2021.100704.
- Chapter 10 Inpatient opioid use disorder treatment for the infectious disease physicianSeval N, Eaton E, Springer S. Chapter 10 Inpatient opioid use disorder treatment for the infectious disease physician. 2021, 189-221. DOI: 10.1016/b978-0-323-68328-9.00010-2.
- Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA TestingSpringer SA, Masciotra S, Johnson JA, Campbell S. Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing. Open Forum Infectious Diseases 2020, 7: ofaa478. PMID: 33204760, PMCID: PMC7651562, DOI: 10.1093/ofid/ofaa478.
- Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.
- A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorderCioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. Journal Of Substance Abuse Treatment 2020, 119: 108146. PMID: 33138929, PMCID: PMC7609980, DOI: 10.1016/j.jsat.2020.108146.
- Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy AgendaSpringer SA, Group O, Barocas J, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda. The Journal Of Infectious Diseases 2020, 222: s230-s238. PMID: 32877568, PMCID: PMC7467230, DOI: 10.1093/infdis/jiz673.
- The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic ReviewSeval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.
- Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS 2020, 34: 1997-2005. PMID: 32826391, PMCID: PMC7606503, DOI: 10.1097/qad.0000000000002673.
- Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid EpidemicSpringer SA, del Rio C. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. Infectious Disease Clinics Of North America 2020, 34: 637-647. PMID: 32782106, PMCID: PMC7414693, DOI: 10.1016/j.idc.2020.06.015.
- Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use EpidemicsSpringer SA, del Rio C. Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics. Infectious Disease Clinics Of North America 2020, 34: xiii-xiv. PMID: 32782107, PMCID: PMC7414777, DOI: 10.1016/j.idc.2020.06.016.
- Integrating Responses to the Opioid Use Disorder and Infectious Disease EpidemicsSpringer SA, Merluzzi AP, del Rio C. Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics. JAMA 2020, 324: 37-38. PMID: 32159771, PMCID: PMC7957328, DOI: 10.1001/jama.2020.2559.
- A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? American Journal On Addictions 2020, 29: 249-267. PMID: 32346932, PMCID: PMC7377168, DOI: 10.1111/ajad.13051.
- Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!Springer SA, Del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clinical Infectious Diseases 2020, 71: 1723-1725. PMID: 32011653, PMCID: PMC7583407, DOI: 10.1093/cid/ciaa111.
- A Call to Action to Combat the Opioid Epidemic Among Women.Springer SA, Biondi BE, Frank C, El-Bassel N. A Call to Action to Combat the Opioid Epidemic Among Women. Journal Of Addiction Medicine 2020, 14: 364-366. PMID: 32011410, PMCID: PMC7392801, DOI: 10.1097/adm.0000000000000622.
- Beyond Antibiotics: A Practical Guide for The Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious DiseasesSeval N, Eaton E, Springer SA. Beyond Antibiotics: A Practical Guide for The Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. Open Forum Infectious Diseases 2019, 7: ofz539. PMID: 31993454, PMCID: PMC6979000, DOI: 10.1093/ofid/ofz539.
- Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populationsCunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.
- Aortic Valve Surgery Outcomes Reporting and Implications for Persons Who Use Drugs With Infectious Endocarditis.Springer SA. Aortic Valve Surgery Outcomes Reporting and Implications for Persons Who Use Drugs With Infectious Endocarditis. Clinical Infectious Diseases 2019, 71: 488-490. PMID: 31588502, PMCID: PMC7530466, DOI: 10.1093/cid/ciz837.
- Reduced Sexual Risk Behaviors Among Persons With Hiv After Release From The Criminal Justice SystemBiondi BE, Frank C, Horn BP, Springer SA. Reduced Sexual Risk Behaviors Among Persons With Hiv After Release From The Criminal Justice System. Open Forum Infectious Diseases 2019, 6: ofz411. PMID: 31660369, PMCID: PMC6788338, DOI: 10.1093/ofid/ofz411.
- Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases.Serota DP, Barocas JA, Springer SA. Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases. Clinical Infectious Diseases 2019, 70: 968-972. PMID: 31420651, PMCID: PMC7319263, DOI: 10.1093/cid/ciz804.
- Pregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research?Biondi BE, Frank C, Springer SA. Pregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research? Journal Of Addiction Medicine 2019, 14: 182-184. PMID: 31403523, PMCID: PMC7059864, DOI: 10.1097/adm.0000000000000565.
- Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder.Springer SA. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder. Clinical Infectious Diseases 2019, 70: 2703-2705. PMID: 31346595, PMCID: PMC7286379, DOI: 10.1093/cid/ciz695.
- Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomesMakarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Abuse Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.
- Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load.Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. Clinical Infectious Diseases 2019, 70: 867-874. PMID: 30994900, PMCID: PMC7319266, DOI: 10.1093/cid/ciz299.
- Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics.Springer SA, Korthuis PT, Del Rio C. Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Annals Of Internal Medicine 2019, 170: 509. PMID: 30934074, DOI: 10.7326/l19-0042.
- Medications for Treatment of Opioid Use Disorder among Persons Living with HIVFanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.
- Brief ReportDelaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 283-287. PMID: 30036277, PMCID: PMC6681811, DOI: 10.1097/qai.0000000000001803.
- Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populationsHussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug And Alcohol Dependence 2018, 194: 59-68. PMID: 30412898, PMCID: PMC6312501, DOI: 10.1016/j.drugalcdep.2018.10.003.
- Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the CommunitySpringer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.
- Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop.Springer SA, Korthuis PT, Del Rio C. Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Annals Of Internal Medicine 2018, 169: 335-336. PMID: 30007032, PMCID: PMC6251491, DOI: 10.7326/m18-1203.
- Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization InitiativeBeckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, Springer SA, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. PLOS ONE 2018, 13: e0197730. PMID: 29787580, PMCID: PMC5963777, DOI: 10.1371/journal.pone.0197730.
- Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the CommunitySpringer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.
- Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice SupervisionMbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, Springer SA. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. Substance Use & Misuse 2018, 53: 1519-1528. PMID: 29333954, PMCID: PMC6432769, DOI: 10.1080/10826084.2017.1416400.
- A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in UkraineMarcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal Of Substance Abuse Treatment 2018, 86: 86-93. PMID: 29415856, PMCID: PMC5808584, DOI: 10.1016/j.jsat.2018.01.003.
- Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in UkraineMarcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.
- Cohort profile: seek, test, treat and retain United States criminal justice cohortChandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.
- Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]Springer SA, Altice FL, Herme M, Di Paola A. Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]. Contemporary Clinical Trials 2017, 57: 98. PMID: 28341227, DOI: 10.1016/j.cct.2017.03.008.
- Corrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. Corrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]. Journal Of Substance Abuse Treatment 2017, 77: 44. PMID: 28476270, PMCID: PMC5458355, DOI: 10.1016/j.jsat.2017.03.008.
- Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the communitySpringer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.
- Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization ConsortiumLoeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS And Behavior 2017, 21: 2945-2957. PMID: 28188460, PMCID: PMC5552433, DOI: 10.1007/s10461-017-1722-9.
- Co-calibration of two self-reported measures of adherence to antiretroviral therapyNance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2016, 29: 464-468. PMID: 27910703, PMCID: PMC5291764, DOI: 10.1080/09540121.2016.1263721.
- Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South AfricaEricsen A, Lauck M, Mohns M, Dinapoli S, Mutschler J, Greene J, Weinfurter J, Lehrer‐Brey G, Crosno K, Peterson E, Reynolds M, Wiseman R, Burwitz B, Sacha J, Friedrich T, Brenchley J, O'Connor D, Xu C, He T, Haret‐Richter G, Franck D, Policicchio B, Brocca‐Cofano E, Ma D, Stock J, Tracy R, Landay A, Wilson C, Apetrei C, Pandrea I, Wong E, Xulu B, Prakadan S, Shalek A, Lalloo U, Baijnath P, Suleman M, Moodley V, Mitha M, Maharaj P, Costiniuk C, Nielsen M, Mhlane Z, Karim F, Lewinsohn D, Ndung'u T, Pasternak A, Prins J, Berkhout B, Leon‐Fuentes L, Viveros‐Rogel M, Vergara‐Mendoza M, Rodriguez‐Castañón M, Cardenas‐Ochoa A, Tello‐Mercado A, Vega C, Sierra‐Madero J, Soto‐Ramirez L, Perez‐Patrigeon S, Hensley‐Mcbain T, Cheu R, Manuzak J, Zevin A, Miller C, Lee E, Wilson C, Burgener A, Klatt N, Mellins C, Abrams E, Dolezal C, Warne P, Elkington K, Bucek A, Leu C, Maskew M, Bor J, MacLeod W, Carmona S, Sherman G, Fox M, Judd A, Chappell E, Doerholt K, Galli L, Giaquinto C, Gibb D, Goetghebuer T, Le Coeur S, Julian A, Turkova A, Goodall R, Collaboration E, Davies M, Sawry S, Phiri S, Rabie H, Eley B, Fatti G, Technau K, Tanser F, Wood R, Giddy J, Bolton‐Moore C, Chimbetete C, Hazra R, Keiser O, Stinson K, Collins I, Team C, Cluver L, Toska E, Orkin M, Yakubovich A, Hodes R, Sherr L, Decroo T, Telfer B, Dores C, Candrinho B, Dos Santos N, Mkwamba A, Dezembro S, Jofrisse M, Ellman T, Metcalf C, Hanrahan C, Keyser V, Schwartz S, Soyizwaphi P, West N, Mutunga L, Steingo J, Bassett J, Van Rie A, Abongomera G, Cook A, Lamorde M, Chabala C, Musiime V, Thomason M, Mulenga V, Colebunders R, Kityo C, Walker S, Gibb D, Team O, Fox M, Bor J, MacLeod W, Maskew M, Brennan A, Stevens W, Carmona S, Brocca‐Cofano E, Xu C, Ma D, Policicchio B, Raehtz K, Dunsmore T, Haret‐Richter G, Sykes C, Keele B, Kashuba, Pandrea I, Apetrei C, Gulick R, Wilkin T, Chen Y, Landovitz R, Amico R, Young A, Richardson P, Marzinke M, Hendrix C, Eshleman S, McGowan I, Andrade A, Hodder S, Klingman K, Chege W, Rinehart A, Rooney J, Andrew P, McCauley M, Mayer K, Team H, McGowan I, Siegel A, Engstrom J, Nikiforov A, Duffill K, Edick S, Mitchell C, Back D, Else L, Egan D, Khoo S, Williams P, Brand R, Cranston R, Grant R, Fonner V, Rodolph M, Liegler T, Glidden D, Baggaley R, Brown E, Palanee‐Philips T, Marzinke M, Hendrix C, Dezutti C, Soto‐Torres L, Baeten J, Kharsany A, Cawood C, Khanyile D, Grobler A, Puren A, Kufa‐Chakeza T, Samsunder N, Frohlich J, Karim Q, George G, Govender K, Toledo C, Chipeta Z, Zembe L, Glenshaw M, Madurai L, Bere A, Deyde V, Riche B, Maman D, Wanjala S, Mendiharat P, Hennequin W, Vandenbulcke A, Mukui I, Subtil F, Ecochard R, Marty L, Cazein F, Pillonel J, Costagliola D, Supervie V, Nelson R, Thompson R, Casavant I, Pals S, Bonzela J, Mugabe D, Come J, Ujamaa D, Cardoso J, Auld A, Maculuve B, Wei S, Shodell D, MacKellar D, Bor J, Brennan A, Fox M, Maskew M, Stevens W, Carmona S, MacLeod W, Logie C, Daniel C, Wang Y, Bozinoff N, Fast D, Long C, Kerr T, Small W, Pannetier J, Ravalihasy A, Le Guen M, Lydié N, Dray‐Spira R, Bajos N, Lert F, du Lou A, Group P, Kuo C, Operario D, Hoare J, Underhill K, Giovenco D, Atujuna M, Mathews C, Stein D, Brown L, Hecht J, Plenty A, Lin J, Charlebois E, Igonya E, Ndimbii J, Guise A, Owiti F, Rhodes T, Strathde S, Deuba K, Anderson S, Ekström A, Pandey, Shrestha R, Karki D, Marrone G, Lyons C, Diouf D, Drame F, Kouamé A, Ezouatchi R, Bamba A, Thiam M, Liestman B, Ketende S, Baral S, Gibbs A, Dunkle K, Khumalo T, Ntini N, Washington L, Mbatha N, Chirwa E, Willan S, Sikweyiya Y, Jama‐Shai N, Jewkes R, Groves A, Reyes H, Moodley D, Maman S, Bukowski L, Coulter R, Riley N, Buehler S, Hoffmann C, Gehr‐Seloover A, Team R, Faden R, Gilbert S, Sullivan K, Cadigan J, Krubiner C, Namey E, Little M, Lyerly A, Mastroianni A, Rao A, Baral S, Phaswana‐Mafuya N, Lambert A, Kose Z, McIngana M, Holland C, Ketende S, Schwartz S, Masvawure T, Lafort Y, Chabeda S, Restar A, Gichangi P, Tocco J, Sandfort T, Mantell J, Tam A, Tumwekwase G, Kabunga E, Russell S, Seeley J, Li C, Zhao Y, Zhang H, Cheng Z, Hong P, Liang X, Gaoshan J, Li L, Tang K, Carrasco M, Kennedy C, Barrington C, Perez M, Donastorg Y, Kerrigan D, Hartson K, Sherman D, Mofelehetsi S, Ncheke T, Khasoane M, Wong J, Fung K, Hui C, Luyombya H, Bisignano A, Maitland D, Poon K, Li A, Perez‐Brumer A, McLean S, Silva‐Santisteban A, Huerta L, de la Grecca R, Mayer K, Sanchez J, Lama, Reisner S, Bonnington O, Wamoyi J, Ddaaki W, Bukenya D, Odongo F, Skovdal M, McLean E, Nyamukapa C, Moshabela M, Wringe A, Chapman S, Chihana N, Scheepers E, Schmitz K, Joseph J, Suggu K, Hariharan N, Esiru G, Yavuz E, Gross J, Mirembe B, Sherr K, Rustagi A, Gimbel S, Nduati R, Cuembelo F, Kone A, Farquhar C, Wasserheit J, Gloyd S, de Schacht C, Team S, Kamanga E, Banda G, Mofolo I, Mwale G, Mwale M, Chikonda J, Sherman J, Chinkonde J, Herce M, Ng'oma K, Mtileni T, Odongo I, Robinson P, Mogashoa M, Bhardwaj S, Holele P, Pillay Y, Goga A, Jackson D, Lombard C, Ramokolo V, Ngandu N, Sherman G, Puren A, Doherty T, Bhardwaj S, Noveve N, Ramraj T, Magasana V, Singh Y, Pillay Y, Group S, Kroon E, Ananworanich J, Eubanks K, Intasan J, Pinyakorn S, Chomont N, Lewin, Palmer S, Trautmann L, Yang H, Chomchey N, Phanuphak N, Cooper K, Phanuphak P, de Souza M, group O, Bekker L, Laher F, Moodie Z, Tomaras G, Grunenberg N, Allen M, Daniels B, Innes C, Mngadi K, Malahleha M, Gilbert P, Michael N, Phogat S, Granados C, Kanesa‐Thasan N, Corey L, Gray G, McElrath J, Team T, Cowan F, Davey C, Mushati P, Mtetwa S, Chiyaka T, Chabata S, Fearon E, Mavedzenge S, Cambiano V, Masuka N, Chemhuru M, Dirawo J, Hanisch D, Hatzold K, Mugurungi O, Busza J, Phillips A, Hargreaves J, Hosek S, Landovitz R, Rudy B, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Rooney J, Wilson C, Interventions T, Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K, Stieh D, Matias E, Fought A, Marx P, Veazey R, Hope T, Ngcapu S, Carias A, Liebenberg L, Werner L, Cianci G, McRaven M, Sibeko S, Garrett N, Kriek J, McKinnon L, Karim S, Karim Q, Passmore J, Hope T, Raehtz K, Haret‐Richter G, Xu C, Policicchio B, Barrenas C, Ma D, Wijewardana V, Brocca‐Cofano E, Stock J, Trichel A, Keele B, Estes J, Katze M, Pandrea I, Apetrei C, Ndhlovu Z, Nkosi T, Mewalal N, Ismail N, Moodley A, Dong K, Ndun'gu T, Walker B, Martin G, Pantazis N, Hoffmann M, Hickling S, Hurst J, Meyerowitz J, Willberg C, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater J, Investigators S, van den Berg K, Vermeulen M, Xulu T, McClure C, Ingram C, Beck G, Stone M, Busch M, Custer B, Murphy E, Study N, Garrett N, Norman E, Asari V, Naicker N, Majola N, Leask K, Karim Q, Karim S, Onoya D, Sineke T, Brennan A, Fox M, Datong P, Jaspan H, Osawe S, Gatei J, Coombs J, Muldoon K, Mallick R, Gray C, Rosenthal K, Cameron D, Abimiku A, Zash R, Souda S, Leidner J, Binda K, Hick C, Powis K, Makhema J, Mmalane M, Essex M, Lockman S, Shapiro R, Jao J, Kacanek D, Williams P, Geffner M, Livingston E, Sperling R, Patel K, Bardeguez A, Burchett S, Chakhtoura N, Scott G, Van Dyke R, Abrams E, Network P, Narendran G, Kumar S, Padmapriyadarsini C, Gomathi N, Menon P, Sekar L, Reddy S, Chandra S, Kumar A, Kumar S, Sekar S, Ravichandran N, Raja K, Lavanya J, Sridhar R, Lakshmi M, Mahilmaran A, Swaminathan S, Atuhumuza E, Yoon C, Katende J, Asege L, Mwebe S, Andama A, Armstrong D, Dowdy D, Kamya M, Semitala F, Cattamanchi A, Ward A, Barr D, Schutz C, Burton R, Boulle A, Maartens G, Wilkinson R, Meintjes G, Flick R, Simon K, Munthali A, Dimba A, Kim M, Kazembe P, Hosseinipour M, Ahmed S, Merle C, Floyd S, Ndiaye A, Galperine T, Furco A, De Jong B, McIlleron H, Glynn J, Sarr M, Bah‐sow O, Affolabi D, Team O, Bräu N, Wyles D, Kottilil S, Darr E, Workowski K, Luetkemeyer A, Adeyemi O, Ruane P, Doehle B, Huang K, Osinusi A, McNally J, Natha M, Guion M, McLean T, Brainard D, McHutchison J, Naggie S, Sulkowski M, Mogalian E, Luetkemeyer A, Naik S, Natha M, Stamm L, Osinusi A, Shen G, Sajwani K, McNally J, Mathias A, Kouamé, Moh R, Boyd A, Badjé A, Gabillard D, N'takpé J, Maylin S, Eholié S, Anglaret X, Danel C, Group A, Rockstroh J, Orkin C, Viani R, Wyles D, Luetkemeyer A, Lazzarin A, Soto‐Malave R, Nelson M, Bhagani, Klinker H, Rizzardini G, Girard P, Shulman N, Hu Y, Fredrick L, Trinh R, Gane E, Kourtis A, Wang L, Wiener J, Liang S, Wei X, Liu W, Chen L, Shepard C, Wang A, Zhang F, Bulterys M, Group T, Molina J, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas‐Castro D, Cua E, Pasquet A, Bernaud C, Rozenbaum W, Delaugerre C, Doré V, Le Mestre S, Simon M, Delfraissy J, Meyer L, Group A, Hucks‐Ortiz C, Lucas J, Wheeler D, Fields S, Caucus T, Wheeler D, Fields S, Nelson L, Hightow‐Weidman L, Magnus M, Shoptaw S, Beauchamp G, Emel L, Piwowar‐Manning E, Chen Y, Watkins P, Mayer K, Team H, Baeten J, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E, Asiimwe S, Morton J, Ngure K, Bulya N, Odoyo J, Tindimwemba E, Haberer J, Marzinke M, Donnell D, Celum C, Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Mwangwa F, Kadede K, Jain V, Plenty A, Lavoy G, Black D, Bukusi E, Cohen C, Clark T, Charlebois E, Kamya M, Havlir D, Team S, Radix A, Carneiro P, Stephanos S, Mosher S, Meacher P, Belkind U, Evans‐Frantz I, Brigham F, Fortenberry A, Comstock L, Vail R, Weiss S, Pena S, Golub S, Garofalo R, Kuhns L, Reisner S, Biello K, Mimiaga M, Bukowski L, Meanley S, Egan J, Matthews D, Stall R, Team T, Bauer G, Shokoohi M, Hammond R, Scheim A, Slogrove A, Judd A, Leroy V, Collaboration C, Naidoo S, Sartorius B, de Vries H, Taylor M, Pettifor A, Wang J, Selin A, Hughes J, Gómez‐Olivé X, Wagner R, MacPhail C, Kahn K, Team H, Kann L, Olsen E, McManus T, Zaza S, Mulligan K, Hosek S, Kapogiannis, Landovitz R, Liu N, Cofield S, Perumean‐Chaney, Havens P, Rutledge B, Wilson C, Team A, Marshall B, Tate J, McGinnis K, Fiellin D, Bryant K, Justice A, Springer S, Azar M, Barbour R, Krishnan A, Altice F, DiPaola A, Baghazal A, Tariko L, Shikely K, Patta S, Omar B, Musyoki H, Bertrand S, Abdallah S, Stone J, Brooks‐Pollock E, Altice F, Azbel L, Smyrnov P, Martin N, Vickerman P, Borquez A, Abramovitz D, Beletsky L, Vickerman P, Gonzales‐Zuñiga P, Rangel G, Hickman M, Strathdee, Martin N, Wall K, Kilembe W, Vwalika B, Haddad L, Khu N, Brill I, Vwalika C, Chomba E, Tichacek A, Allen S, Darbes L, McGrath N, Johnson M, Hosegood V, Fritz K, Ngubane T, van Rooyen H, Ruark A, Brewster‐Lee D, Hembling J, Davis V, Renju J, Wringe A, Crampin A, Koole O, Nyirenda C, Namadingo H, McLean E, Network A, Li L, Liang L, Lin C, Xiao Y, Ji G, Irani L, McGinn E, Mellish M, Mtema O, Dindi P, Imakit R, Ajok S, Talima D, Namakula A, Allen H, Fair C, Trexler C, D'Angelo L, Stadler J, Chikandiwa A, Mayaud P, Rees H, Imrie J, Delany‐Moretlwe S, Taylor T, Oberth G, Mumba O, Bhayani L, Russell A, Mwanza F, Milanga M, Nandelenga R, Namutamba D, Albert‐Hope C, Gustav R, Simon Y, Castellanos E, Irwin R, Holloway I, Steward W, Mortimer J, Curtis P, Van Gorder D, Leibowitz A, Morin S, Mulhern‐Pearson C, Donnelly A, King A, Fox A, Pulsipher C, Evans D, Lemp G, Baral S, Lyons C, Sullivan E, Kurani S, Sherwood J, Millett G, MacAllister J, Zanolini A, Chipungu J, Bosomprah S, Mafwenko M, Holmes C, Thirumurthy H, Qin Y, Liu F, Tang W, Tang S, Liu C, Mao J, Zhang W, Taege A, Nowacki A, Wei C, Tucker J, Madanhire C, Sibanda E, Ruhode N, Hatzold K, Cowan F, Mavedzenge, Manjezi N, Fatti G, Mothibi E, Shaikh N, Oyebanji O, Grimwood A, Sibanda E, Tumushime M, Mufuka J, Gudukeya S, Mavedzenge S, Bautista‐Arredondo S, Thirumurthy H, McCoy S, Padian N, Hatzold K, Copas A, Cowan F, Dougherty G, Clarke K, Fayorsey R, Kamonga M, Kimambo S, Lutkam D, Madevu‐Matson C, Mtiro H, Msuka S, Mugisha V, Panya M, Ramadhani A, Sipemba J, Urasa P, Rabkin M, Granich R, Gupta S, Hall I, Aberle‐Grasse J, Hader S, Mermin J, Koenig S, Dorvil N, Severe P, Riviere C, Faustin M, Perodin C, Paul C, Apollon A, Saintil G, Duverger L, Dumont E, Hedt‐Gauthier B, Hennessey K, Rivera V, Devieux J, Pape J, Kitheka M, Curran K, Gathii P, Mudany M, Bii S, Bor J, Ahmed S, Fox M, Rosen S, Katz I, Tanser F, Pillay D, Bärnighausen T, MacKellar D, Maruyama H, Weber R, Ernest O, Porter S, Gikaro J, Alexander G, Kundi G, Byrd J, Kazaura K, Mbilinyi D, Morales F, Justman J, Josiah R, McNairy M, Lamb M, Gachuhi A, Nuwagaba‐Biribonwoha H, Burke S, Mazibuko S, Okello V, Ehrenkranz P, Sahabo R, El‐Sadr W, Group L, Dhodho M, Frieden M, Shroufi A, Wanjiru E, Daho S, Simons E, Bygrave H, Giuliani R, Torrens A, Molfino L, Silva C, Ellman T, Magaia A, van Dijk J, Kamenova K, Shamu A, Pfeiffer K, Hobbins M, Ehmer J, Murungu J, Barnabas R, Coombs R, Chang M, Schaafsma T, Asiimwe S, Thomas K, Baeten J, Celum C, Moyo S, Mohammed T, Wirth K, Bennett K, Holme M, Mupfumi L, Sebogodi P, Moraka N, Boleo C, Maphorisa C, Seraise B, Gaseitsiwe S, Musonda R, van Widenfelt E, Powis K, Gaolathe T, Tchetgen E, Makhema J, Essex M, Lockman S, Novitsky V, Brigstock‐Barron O, Logan L, Sowerbutts H, Womack V, Osman M, Anderson J, Nardone A, Pinkevych M, Reynaldi A, Fennessey C, Reid C, Nadella P, Lipkey L, Newman L, Ayala V, Jain S, Del Prete G, Estes J, Ott D, Lifson J, Ohlen C, Keele B, Davenport M, Kaminski R, Hu W, Karn J, Khalili K, Peterson C, Wang J, Polacino P, Hu S, Holmes M, Kiem H, Bozzi G, Watters S, Simonetti F, Anderson E, Gorelick R, Shao W, Bell J, Rehm C, Dewar R, Yarchoan R, Uldrick T, Maldarelli F, Wensing A, Diez‐Martin J, Huetter G, Kuball J, Kwon M, Nijhuis M, Saez‐Cirion A, Rocha V, Salgado M, Wiesch J, Stam A, Martinez‐Picado J, Huang L, Lai W, Zhu L, Chen C, Felber B, Hu X, Valentin A, Dayton F, Cai Y, Rosati M, Alicea C, Sardesai N, Gautam R, Martin M, Mullins J, Pavlakis G, Koofhethile C, Ndhlovu Z, Thobakgale C, Prado J, Ismail N, Mncube Z, Mkhize L, van der Stok M, Yende N, Walker B, Goulder P, Ndung'u T, Cohort S, Worley M, Kelleher A, Kent S, Chung A, Okala S, King D, Shattock R, He T, Policicchio B, Brocca‐Cofano E, Stock J, Xu C, Raehtz K, Gaufin T, Gautam R, Pandrea I, Apetrei C, Mylvaganam G, Hicks S, Lawson B, Nega M, Velu V, Ahmed R, Freeman G, Amara R, Steele S, Arellano G, Ellman T, Shroufi A, Van Cutsem G, Oldenburg C, Bor J, Tanser F, Mutevedzi T, Shahmanesh M, Seage G, De Gruttola V, Mimiaga M, Mayer K, Pillay D, Bärnighausen T, Currier J, Britto P, Hoffman R, Brummel S, Masheto G, Joao E, Santos B, Aurpibul L, Losso M, Pierre M, Weinberg A, Chakhtoura N, Browning R, Coletti A, Shapiro D, Pilotto J, Team P, Munderi P, Were E, Avihingsanon A, Mbida P, Mohapi L, Samba B, Jansen M, Mohammed P, Sawyerr G, Barnes P, van Delft Y, Odongpiny E, Nalwanga D, Kaimal A, Kiragga A, Nabaggala S, Castelnuovo B, Parkes‐Ratanshi R, Stranix‐Chibanda L, Brummel S, Angelidou K, Tierney C, Coletti A, McCarthy K, Pilotto J, Mutambanengwe M, Chanaiwa V, Mhembere T, Kamateeka M, Masheto G, Chamanga R, Maluwa M, Hanley S, Joao E, Theron G, Chandawale A, Nyathi M, Santos B, Aurpibul L, Mubiana‐Mbewe M, Oliveira R, Basar M, Chakhtoura N, Browning R, Currier J, Fowler, Team P, Molina J, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka M, Vanderkerckhove L, Benfield T, Munroe D, Lundgren J, Group J, Arenas‐Pinto A, Grund B, Sharma S, Martinez E, Cummins N, Fox J, Klingman K, Sedlacek D, Collins S, Flynn P, Chasanov, Kedem E, Katlama C, Sierra‐Madero J, Ormaasen V, Brouwers P, Cooper D, Group F, Lake J, Trottier B, Garcia‐Diaz J, Edelstein H, Kumar P, Bredeek U, Loutfy M, Brennan C, Koteff J, Wynne B, Hopking J, Aboud M, Kerrigan D, Mantsios A, Margolis D, Murray M, Orrell C, Hagins D, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man C, Aylott A, Buchanan A, Wynne B, Vavro C, Aboud M, Smith K, Margolis D, Podzamczer D, Stellbrink H, Lutz T, Angel J, Richmond G, Clotet B, Gutierrez F, Sloan L, Griffith S, St Clair M, Dorey D, Ford S, Mrus J, Crauwels H, Smith K, Williams P, Spreen W, Bavinton B, Phanuphak N, Jin F, Zablotska I, Grinsztejn B, Prestage G, Grulich A, Group O, Couderc C, Keita B, Anoma C, Wade A, Ouédraogo A, Coulibaly A, Ehouman S, Diop A, Somda M, Yomb Y, Henry E, Spire B, Laurent C, Mendizabal‐Burastero R, Galindo‐Arandi C, Yancor M, Vela I, Aguilar‐Martinez J, Paz‐Bailey G, Hoots B, Xia M, Finlayson T, Prejean J, Purcell D, Group F, Hightow‐Weidman L, Magnus M, Beauchamp G, Hurt C, Shoptaw S, Emel L, Piwowar‐Manning E, Mayer K, Nelson L, Wilton L, Watkins P, Fields S, Wheeler D, Tong C, Suzan‐Monti M, Sagaon‐Teyssier L, Ossanga O, Laurent C, Maradan G, Ambani A, Vidal L, Spire B, Boyer S, Group E, Phillip R, Mudzviti T, Shamu T, Chimbetete C, Rakhmanina N, Corrigan B, Kose J, Manson K, Collaborative N, Cawley C, Oti S, Njamwea B, Nyaguara A, Odhiambo F, Otieno F, Njage M, Shoham T, Church K, Todd J, Zaba B, Wringe A, Network A, Bivol S, Catranji V, Caraulan L, Lucas J, Karuna S, Hinson K, Sista N, Yola N, Ntombela F, Mgodi N, Luthuli N, Wakefield S, Andrew P, Greene E, Delany‐Moretlwe S, Gray G, White R, McCoy S, Njau P, Fahey C, Czaicki N, Kapologwe N, Kadiyala S, Dow W, Jewell N, Padian N, Jagessar N, Papua L, Ndunda E, Wijne M, Hendriks S, Khoza N, Stadler J, MacPhail C, Chikandiwa A, Brahmbhatt H, Delany‐Moretlwe S, Toska E, Cluver L, Boyes M, Isaacsohn M, Hodes R, Sherr L, Study M, Bermudez L, Jennings L, Ssewamala F, Nabunya P, Mellins C, McKay M, Fagan T, Zulu C, Zeng W, Menon V, Korenromp E, Haacker M, Turay M, Rotich K, Strauss M, Barihuta T, Semini I, Stover J, Nitschke A, Forster N, Poku N, Dutta A, Barker C, Lazar L, Grosso A, Millett G, Honermann B, Sherwood J, MacAllister J, Lindsey K, Chandra C, Blumenthal S, Lyons C, Baral S, Donaldson E, Mattur D, Fisher K, Harmon T, Harrison P, Izazola‐Licea J, Naeveke A, Warren M, Irani L, McGinn E, Mellish M, Mtema O, Dindi P, Faye S, Johns B, Baruwa E, Ambrose K, Bassett I, Hong T, Drain P, Govere S, Thulare H, Krows M, Moosa M, Mhlongo B, Wexler D, Huang M, Frank S, Hyle E, Parker R, Mukuye A, Lukoda N, Crandall B, Bryant H, Oliveras E, Colua E, Marinda E, Campbell, Gustafson K, Jalan P, Ngauv B, Sovannarith S, Wilhelm A, Sopheap S, Vichea C, Middlecote C, Sun L, Kgwaadira B, Katlholo T, Fiebig L, Boyd R, Wame M, Kuate L, Agegnehu D, Dikobe W, Sangrujee N, Petlo C, Nkomo B, Avalos A, Skiles M, Phillips H, Wuhib T, Finlay‐Vickers A, Stegman P, Kripke K, Njeuhmeli E, Samuelson J, Schnure M, Dalal S, Farley T, Hankins C, Thomas A, Reed J, Bock N, Durand‐Zaleski I, Mutuon P, Charreau I, Temblay C, Rojas D, Chas J, Chidiac C, Capitant C, Spire B, Meyer L, Molina J, Ipergay A, Luz P, Osher B, Grinsztejn B, MacLean R, Losina E, Struchiner C, Parker R, Freedberg K, Mesquita F, Walensky R, Veloso V, Paltiel A, Shiino T, Hattori J, Sadamasu K, Nagashima M, Hachiya A, Sugiura W, Yoshimura K, Network T, Villaran M, Brezak A, Ahmed S, Ulrich A, Duerr A, Herbeck J, Mullins J, Seto E, Morgan E, Nyaku A, D'Aquila R, Schneider J, de Oliveira T, Khumalo P, Cawood C, Dellar R, Tanser F, Hunt G, Grobler A, Kharsany A, Madurai L, Karim Q, Karim S, Hora B, Gulzar N, Chen Y, Cai F, Su C, Karagiannis K, Smith K, Simonyan V, Shah, Ahmed M, Sanchez A, Stone M, Cohen, Haynes B, Busch M, Mazumder R, Denny T, Gao F, Hakim J, Musiime V, Szubert A, Siika A, Mallewa J, Agutu C, Pett S, Bwakura‐Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Maitland K, Griffiths A, Kityo C, Mugyenyi P, Prendergast A, Walker A, Gibb D, Team R, Kityo C, Siika A, Szubert A, Mallewa J, Bwakura‐Dangarembizi M, Kabahenda S, Mwaringa S, Pett S, Griffiths A, Lugemwa A, Wachira S, Musoro G, Rajapakse C, Etyang T, Abach J, Wavamunno P, Nyondo‐Mipando L, Reid A, Nathoo K, Hakim J, Gibb D, Walker A, team R, Cahn P, Kaplan R, Sax P, Squires K, Molina J, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Xu X, Rodgers A, Rawlins S, Nguyen B, Leavitt R, Teppler H, Group F, Cahn P, Rolón M, Figueroa M, Gun A, Patterson P, Sued O, Patel V, Rawat S, Lelutiu‐Weinberger C, Dange A, Kamath C, Poojary R, Bisht M, Golub, Jamil, Prestage G, Fairley C, Grulich A, Smith K, Chen M, Holt M, McNulty A, Bavinton B, Conway D, Wand H, Keen P, Bradley J, Kolstee J, Batrouney C, Russell D, Law M, Kaldor J, Guy R, Shenoi S, Moll A, Madi J, Guddera V, Madondo T, Turner D, Brooks R, Kyriakides T, Andrews L, Friedland G, Thirumurthy H, Masters S, Obonyo B, Mavedzenge S, Maman S, Omanga E, Agot K, Iwuji C, Orne‐Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, Okesola N, Makowa T, Dreyer J, Herbst K, Grath N, Barnighausen T, Boyer S, De Oliveira T, Rekacewicz C, Bazin B, Newell M, Pillay D, Dabis F, Group F, Bernard E, Eba P, Kazatchkine C, Müller A, Daskilewicz K, Spencer S, Meer T, Artz L, Saha A, Grant C, Patel P, Getahun M, Sellers T, Ndeogo T, Blantari J, Awotwi E, Saunders P, Outlaw S, Demeri D, McCracken J, Hagos K, King C, Shubert V, Daskalakis D, Tietz D, Harrington M, Smith K, Ferrusi C, Kavanagh M, Bhardwaj K, Tomlinson C, Hu Y, Waterhouse C, Rutter L, Amin T, Radhakrishnan P, Mellouk O, Di Giano L, Babikhina K, Golovin S, Fonseca E, Bastos F, Siegler A, Liu A, Mayer K, Thure K, Fish R, Andrew E, Gelman M, Sullivan P, Mansoor L, Karim Q, Mngadi K, Montague C, Yende‐Zuma N, Dawood H, Gengiah T, Samsunder N, Baxter C, Schwartz J, Doncel G, Ntombela F, Grobler A, Karim S, Wyatt M, Pisarski E, Tam M, Nakku‐Joloba E, Muwonge T, Katabira E, Ware N, Gibson S, Crouch P, Hecht J, Gagliano J, Patriarca T, Auerbach J, Grant R, Lyon W, Hall C, Zablotska I, Grulich A, Guy R, Amin J, Selvey C, Schmidt H, Price K, Cooper D, Group E, Mugwanya K, Heffron R, Wyatt C, Mugo N, Celum C, Kiarie J, Katabira E, Ronald A, Baeten J, Teams F, Cawley C, Nicholas S, Szumilin E, Perry S, Quiles I, Masiku C, Wringe A, Jefferys L, Hector J, Hobbins M, Ehmer J, Anderegg N, Shade S, Chang W, Kahn J, Mwai D, Mwangwa F, Kwarisiima D, Owaraganise A, Ayieko J, Havlir D, Kamya, Charlebois E, Petersen M, Clark T, Bukusi E, Cohen C, Jain V, Pasipamire L, Kerschberger B, Zabsonre I, Ndlovu S, Sibanda G, Mamba S, Mazibuko S, Lukhele N, Kabore S, Rusch B, Jakubowski A, Kabami J, Mwai D, Snyman K, Clark T, Ayieko J, Owaraganise A, Mwangwa F, Petersen M, Cohen C, Bukusi E, Kamya M, Havlir D, Charlebois E, Thirumurthy H, Nofemela A, Kalombo C, Orrell C, Myer L, Ngandu N, Carlson J, Chopera D, Ndabambi N, Goodier S, Garrett N, Samsunder N, Karim Q, Karim S, Williamson C, Rolland M, Tovanabutra S, Kijak G, Sanders‐Buell E, Bose M, Owen C, Maganga L, Nitayaphan S, Rono K, Sekiziyivu A, Eller L, Kim J, Michael N, Robb M, Palmer B, Neff C, Li S, Schneider J, Campbell T, Lozupone C, Byrne E, Anahtar M, Cohen K, Moodeley A, Padavattan N, Ismail N, Bowman B, Olson G, Mabhula A, Leslie A, Ndung'u T, Walker B, Ghebremichael, Dong K, Kwon D, Liebenberg L, McKinnon L, Leask K, Rositch A, Garrett N, Samsunder N, Kharsany A, Grobler A, Singh A, Passmore J, Karim S, Karim Q, Martinez S, Campa A, Huffman F, Makhema J, Moyo S, Williams O, Marlink R, Baum M, Mutenda N, Nakanyala T, Hamunime N, Mekonen T, Tjituka F, Natanael S, Mazibuko G, Mwinga S, Mabirizi D, Sagwa E, Walkowiak H, Kiesling A, Aptekar S, Jordan M, Hong S, Zapiola I, Cecchini D, Giuliano S, Martinez M, Rodriguez C, Bouzas M, Dzissyuk N, Abishev A, Zhanpeisova A, Nagashbekova G, Tazhibayeva G, Schramm B, Carnimeo V, Rakesh A, Ardiet D, Cossa L, Bouchaud O, Alloui C, Oo W, Dias P, Mukui I, Omwoyo W, Manuel R, de Pedro A, Telnov A, Chirwa Z, Chilima B, Nicholas S, Vubil A, Serrano L, Opolo V, Zeh C, Peeters M, Molfino L, Salumu L, Vandenbulcke A, Amoros I, Etard J, Rodríguez M, Balkan S, Szumilin E, Thompson J, Kityo C, Walker A, Hakim J, Kambugu A, van Oosterhout J, Siika A, Mweemba A, Van den Eede P, Dunn D, Paton N, Team F, Díaz A, Casado J, Dronda F, Gómez‐Ayerbe C, Vivancos M, Bañón S, Quereda C, Serrano S, Moreno A, Navas E, Rodríguez M, Pérez‐Elías M, Moreno S, Grobler A, Kharsany A, Cawood C, Khanyile D, Puren A, Madurai L, MacLeod W, Fraser N, Bor J, Shubber Z, Carmona S, Pillay Y, Gorgens M, Moyo S, Mohammed T, Kotokwe K, Boleo C, Mupfumi L, Gaseitsiwe S, Musonda R, Bennett K, van Widenfelt E, Gaolathe T, Mmalane M, Holme M, Khan N, Wang R, Wirth K, Tchetgen E, Lockman S, Makhema J, Essex M, Novitsky V, Nakanyala T, Patel S, Sawadogo S, Maher A, Banda K, Wolkon A, Chaturvedi S, Luphala P, Agovi A, Chipadze, Ntema C, Prybylski D, Mabuku I, Lowrance D, Hamunime N, Agolory S, McFarland W, Rodger A, Lampe F, Burman W, Gruhlich A, Friedland G, El‐Sadr W, Neaton J, Emery S, Corbelli G, Molina J, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips A, Group F, Masuka N, Goverwa‐Sibanda T, Maphosa T, Tshuma E, Kurauone W, Ngarivume K, Masungo T, Carroll R, Greiger‐Zanlungo P, Blick G, Raw A, Lakhani I, Dlamini D, Munthali A, Chinsinga B, Kadzandira J, Ngwira B, Masiye F, Kaunda‐Khangamwa B, Torriente A, Licata M, Mabhele S, Virga A, Nininahazwe C, Ndayizeye N, Kabanga J, project T, Stangl A, Singh D, Windle M, Sievwright K, Footer K, Iovita A, Mukasa S, Baral S, Davis S, Hart M, de Lima C, De Castro D, de Lima Pereira M, Santana D, Aguiar P, Myers L, Hajiyiannis H, Motuba T, Delate R, Mahlasela L, Biello K, Coffey‐Esquivel J, Hosek S, Belzer M, Sullivan P, Mimiaga M, Oleson S, Taylor S, Kreh L, Mayer K, Souleymanov R, Brennan D, Lachowsky N, Fantus S, Ceranto A, Remien R, Mellins C, Robbins R, Gouse H, Leu C, Rowe J, Henry M, Myer L, Stein D, Joska J, Mathias A, Abreu L, Zampieri T, Spiassi A, Gutierrez E, Tun W, Aung P, Bajracharya A, Yam E, Ryan C, Oo S, Thein Z, Paing A, Pasricha N, Willenberg L, Agius P, Sein T, Htun S, Latt N, Luchters S, Vu L, Pulerwitz J, Zieman B, Okal J, Yam E, Project L, Anderson A, Stern E, Mokganyetji T, Rebombo D, MacPhail C, Khoza N, Treves‐Kagan S, Selin A, Peacock D, Pettifor A, Lippman S, Kahn K, Twine R, Gibbs A, Ntini N, Khumalo T, Washington L, Mbatha N, Chirwa E, Willan S, Sikweyiya Y, Jama‐Shai N, Jewkes R, McClair T, Hossain T, Sultana N, Yam E, Zieman B, Hossain S, Yasmin R, Sadiq N, Carter A, Greene S, Hankins C, Brotto L, Money D, Kestler M, Patterson S, O'Brien N, Salters K, Ding E, Webster K, Nicholson V, Sanchez M, Desbiens M, Dubuc D, Lin S, Hogg R, de Pokomandy A, Loutfy, Kaida A, Team C, Chirowodza A, Williams D, Diergaardt C, Adetokunboh O, Gede S, Gobodo N, Makeleni N, Tuswa N, Eckard M, O'rie T, Shingwenyana N, Green B, Oluwatimilehin I, Jacobs D, Mabuse R, Maartens T, Dikgale F, Sithole J, Thambinayagam A, Ndirangu J, Leonard W, Uwamahoro D, Uwacu T, Ishimwe A, Mutaganzwa A, Chang E, Ngirabega J, Mwakangalu D, Nzaro M, Mwamzandi Y, Mwero B, Makori J, Mlongo R, Bunu A, Kegoli S, Njoroge A, Motoku J, Muriithi C, Mutisya I, Cale E, Gorman J, Radakovich N, Ozorowski G, Crooks E, Osawa K, Asokan M, Doria‐Rose N, Ward A, Kwong P, Binley J, Mascola J, Ranasinghe S, Lamothe‐Molina P, Soghoian D, Kaizer S, Cole M, Shalek A, Yosef N, Jones B, Carrington M, Streeck H, Kaufmann D, Picker L, Kappler J, Walker B, Mduluza T, Dzoro S, Bedi K, Mpoloka W, Dutrieux J, Maarifi G, Portilho D, Arhel N, Chelbi‐Alix M, Nisole S, Chen S, Tang J, Chen Z, Mocroft A, Achra A, Ross M, Ryom L, Avihingsanon A, Bakowska E, Belloso W, Clarke A, Furrer H, Lucas G, Ristola M, Rassool, Ross J, Somboonwit C, Wyatt C, Group O, Maponga T, Vermeulen H, Robertson B, Burmeister S, Preiser W, Kew M, Andersson M, Bucek A, Leu C, Benson S, Warne P, Abrams E, Elkington K, Dolezal C, Wiznia A, Mellins C, Mogambery J, Dawood H, Wilson D, Moodley A, Alejos B, Hernando V, del Amo J, Rubio R, Montero M, Rivero M, Hernández‐Quero J, Muga R, Gutierrez F, Moreno S, Coris, Mosepele M, Mokgatlhe L, Hudson P, Letsatsi V, Gross R, Nyaboke I, Pengo V, Ojuok S, Athiambo M, Okello E, Otieno F, Plank R, Bailey R, Little M, Fox A, Agot K, Grund J, Mboya E, Musingila P, Omanga E, Emusu D, Odoyo‐June E, Ohaga S, Otieno‐Nyunya B, Awori Q, Lee R, Li P, Ouma D, Obura N, Oundo M, Mwamkita D, Chirchir B, Barasa M, Kirui M, Macharia P, Oketch J, Otiende P, Nyangweso N, Maina M, Kiswi N, Goldstein M, Nyanchoka J, Barone M, Kaufman M, Dam K, Hatzold K, Van Lith L, Ncube G, Lija G, Bonnecwe C, Mavhu W, Kahabuka C, Seifert‐Ahanda K, Marcell A, Mahlasela L, Figueroa M, Njeuhmeli E, Tobian A, Group A, Adera F, Young M, Adipo T, Otieno F, Nordstrom S, Mehta S, Bailey R, McClelland R, Lingappa, John‐Stewart G, Kinuthia J, Yuhas K, Jaoko W, Srinivasan S, Mandaliya K, Fiedler T, Munch M, Richardson B, Overbaugh J, Fredricks D, Decker M, Tomko C, Wingo E, Peitzmeier S, Sawyer A, Glass N, Sherman S, van der Straten A, Shapley‐Quinn M, Reddy K, Cheng H, Etima J, Woeber K, Musara P, Palanee‐Phillips T, Baeten J, Montgomery E, Team M, Maughan‐Brown B, Evans M, George G, Rosenberg M, Pettifor A, Twine R, Hughes J, Gomez‐Olive F, Wagner R, Selin A, MacPhail C, Kahn K, Stadler J, Delany‐Moretlwe S, Baron D, Ju S, Gray G, Rees H, Group F, Moshabela M, Bukenya D, Darong G, Wamoyi J, Zuma T, Renju J, Nyamukapa C, Ddaaki W, Bonnington O, Seeley J, Hoosegood V, Wringe A, Audet C, Ngobeni S, Wagner R, Abdallah S, Ibrahim F, Kirimo M, Mongi A, Baya J, Shossi M, Omar A, Nomsenge S, Thomas A, Hoddinott G, Carolus G, Bond V, Team A, Dube F, Dube M, Mpofu A, Magure T, Taramusi I, Pacahuala C, Stratton T, Masching R, King A, Aspin C, Omare J, Kituku A, McLean E, Renju J, Wamoyi J, Bukenya D, Ddaaki W, Church K, Wringe A, Network A, Barron P, Pillay Y, Sebidi J, Fernandes A, Adeyemi O, Erekaha S, Ogum E, Yunusa F, Swomen H, Barde A, Chime C, Ebagua I, Sam‐Agudu N, Dinanga J, Gill M, Loando A, Nyombe C, Bakwalufu J, Mbonze N, Fwamba F, Ilunga V, Machekano R, Phillips T, Brittain K, Abrams E, Zerbe A, Ronan A, Mellins C, Remien R, Woelk G, Kieffer M, Mpofu D, Cathcart R, Group A, Azizuyo B, Mantsios A, Shembilu C, Mbwambo J, Likindikoki S, Beckham S, Mwampashi A, Leddy A, Galai N, Davis W, Kerrigan D, Duck T, Selvey C, Telfer B, Schmidt H, Price K, Keen P, Cecilio M, Holden J, Vannakit R, Jantarapakde J, Pengnonyang S, Jitjang S, Janamnuaysook R, Pankam T, Trachunthong D, Pussadee K, Reankhomfu R, Lingjongrat D, Janyam S, Nakpor T, Leenasirimakul P, Jadwattanakul T, Noriega S, Charoenying S, Sattayapanich T, Arunmanakul A, Phanuphak P, Cassell M, Phanuphak N, Arthos J, Byrareddy S, Cicala C, Ortiz K, Little D, Gumber S, Hong J, Zurla C, Villinger F, Fauci A, Ansari A, Santangelo P, Gosselin A, Salinas T, Planas D, Wacleche V, Zhang Y, Fromentin R, Mehraj V, Chomont N, Routy J, Ancuta P, Policicchio B, Xu C, Ma D, He T, Raehtz K, Sivanandham R, Kleinman A, Krampe N, Haret‐Richter G, Dunsmore T, Apetrei C, Pandrea I, Ribeiro R, Mota T, Khoury G, Jacobson J, Lu H, Wightman F, Van der Sluis R, Anderson J, Cameron P, Lewin, Purcell D, Hope T, Mamede J, Leidner J, Williams P, Mayondi G, Ajibola G, Holding P, Tepper V, Nichols S, Diseko M, Magetse J, Sakoi M, Moabi K, Makhema J, Mdluli C, Chaudhury S, Petlo C, Jibril H, Kammerer B, Lockman S, Boivin M, Sikorskii A, Aizire J, Maliwichi‐Senganimalunje L, Ogwang L, Kawalazira R, Nyakato M, Familiar I, Ruisenor‐Escudero H, Mallewa M, Taha T, Fowler, McHenry M, Apondi E, Ayaya S, Tu W, Bi G, Sang E, Vreeman R, Njuguna N, Ngure K, Bukusi D, Wamalwa D, Mugo N, Majonga E, Rylance J, Odland J, Kranzer K, McHugh G, Metcalfe J, Bandason T, Mujuru H, Kaski J, Ferrand R, Puthanakit T, Kosalaraksa P, Petdachai W, Hansudewechakul R, Borkird T, Lolekha R, Thaisri H, Samleerat T, Boonsuk S, Ongwandee S, Group O, Wake R, Jarvis J, Harrison T, Mashamaite S, Govender N, Ramjathan P, Reddy N, Mlisana K, Manak M, Shutt A, Hack H, Jagodzinski L, Peel S, Danboise B, Tang N, Pahalawatta V, Frank A, Lampinen J, Leckie G, Bilkovski R, Bagley Z, Viana R, Wallis C, Abravaya K, Kulkarni S, Jadhav S, Khopkar P, Sane S, Chimanpure V, Dhilpe V, Londhe R, Ghate M, Yelgate R, Panchal N, Rahane G, Rewari B, Gangakhedkar R, Sutcliffe C, Thuma P, Sinywimaanzi K, Hamahuwa M, Moss W, Davey D, Wall K, Inambao M, Kilembe W, Brill I, Chomba E, Khu N, Mulenga J, Tichacek A, Vwalika B, Allen S, Group R, Heffron R, Mugo N, Ngure K, Bukusi E, Odoyo J, Katabira E, Bulya N, Asiimwe S, Tindimwebwa E, Haberer J, Marzinke M, Celum C, Baeten J, Maman D, Huerga H, Van Cutsem G, Mukui I, Chilima B, Hennequin W, Masiku C, Salumu L, Ellman T, Etard J, Schwartz S, Phofa R, Yende N, Bassett J, Sanne I, Van Rie A, Davies N, Mullick S, Schwartz S, Kaida A, Kabakyenga J, Bwana M, Bajunirwe F, Bennett K, Haberer J, Boum Y, Martin J, Hunt P, Bangsberg, Matthews, Moodley K, Staunton C, Duby Z, Hendricks M, Roussow T, de Roubaix M, Nair G, Skinner D, Salzwedel J, Hannah S, Taylor J, Dube K, Power J, Lucke J, Dowsett G, Brown G, Lyons A, Evans D, Taylor J, Sylla L, Garner S, Weiner B, Skinner A, Greene S, Rennie S, Dubé K, Garner S, Rennie S, Ananworanich J, Dube K, Margolis D, Sugarman J, Tressler R, Gilbertson A, Dawson L, Mathews A, Anderson A, Farley S, Hightow‐Weidman L, Muessig K, Rennie S, Tucker J, Kiriazova T, Sereda Y, Neduzhko O, Postnov O, Yorick R, Shvab I, Dvoriak S, Garone D, Mateyu G, van Oosterhout J, Singano V, van Schoor V, Chigayo M, Ndindi H, Kwekwesa A, Gaven S, Harawa K, Zandamela A, Mobaracaly, Benedetti M, Solomon D, Bernardo V, Topp S, Moonga C, Mudenda C, Chileshe C, Magwende G, Heymann S, Henostroza G, Ingleby C, Ayalew M, Ponde T, Wall K, Inamba M, Kilembe W, Karita E, Vwalika B, Mulenga J, Parker R, Sharkey T, Tichacek A, Hunter E, Yohnka R, Abdallah J, Allen S, Galarraga O, Wamai R, Sosa‐Rubi S, Mugo M, Contreras D, Bautista‐Arredondo S, Nyakundi H, Wang'ombe J, Wilhelm A, Amole C, Middlecote C, Harwell J, McCarthy E, Sosa‐Rubí S, Bautista‐Arredondo S, Opuni M, Contreras‐Loya D, La Hera‐Fuentes G, Salas‐Ortiz A, Kwan A, Condo J, Dzekedzeke K, Galárraga O, Martinson N, Masiye F, Nsanzimana S, Wamai R, Wang'ombe J, Torres‐Rueda S, Weiss H, Wambura M, Mahler H, Chilongani J, Kuringe E, Hayes R, Plotkin M, Makokha M, Hellar A, Schutte C, Mshana G, Larke N, Lija G, Changalucha J, Grund J, Terris‐Prestholt F, Gotham D, Barber M, Fortunak J, Pozniak A, Hill A. Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa. Journal Of The International AIDS Society 2016, 19: 21264. PMID: 27460772, PMCID: PMC4960637, DOI: 10.7448/ias.19.6.21264.
- Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in UkraineMakarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-220. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.
- Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]Springer S, Brown S, Di Paola A. Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]. Drug And Alcohol Dependence 2016, 161: 372. PMID: 28463553, PMCID: PMC4871258, DOI: 10.1016/j.drugalcdep.2016.02.009.
- Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice systemSpringer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.
- The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic ReviewVagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review. Current HIV/AIDS Reports 2015, 12: 421-436. PMID: 26412084, PMCID: PMC4643391, DOI: 10.1007/s11904-015-0285-5.
- HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site studyVagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2015, 28: 22-31. PMID: 26275122, PMCID: PMC4713253, DOI: 10.1080/09540121.2015.1062464.
- An exploratory study of therapeutic misconception among incarcerated clinical trial participantsChristopher PP, Stein MD, Springer SA, Rich JD, Johnson JE, Lidz CW. An exploratory study of therapeutic misconception among incarcerated clinical trial participants. AJOB Empirical Bioethics 2015, 7: 24-30. PMID: 26709382, PMCID: PMC4687735, DOI: 10.1080/23294515.2015.1058303.
- Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global PerspectiveSpringer SA, Larney S, Alam-mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: s155-s161. PMID: 25978482, PMCID: PMC4443704, DOI: 10.1097/qai.0000000000000637.
- Correction: The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical ModelLima VD, Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JS, Spaulding A. Correction: The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLOS ONE 2015, 10: e0128734. PMID: 25978721, PMCID: PMC4433341, DOI: 10.1371/journal.pone.0128734.
- The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical ModelLima VD, Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JS, Spaulding A. The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLOS ONE 2015, 10: e0123482. PMID: 25905725, PMCID: PMC4408043, DOI: 10.1371/journal.pone.0123482.
- Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational StudyLincoln T, Simon-Levine D, Smith J, Donenberg GR, Springer SA, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. Journal Of Correctional Health Care 2015, 21: 125-139. PMID: 25788608, PMCID: PMC4433291, DOI: 10.1177/1078345815574566.
- Validation of a Brief Measure of Opioid DependenceWickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence. Journal Of Correctional Health Care 2015, 21: 12-26. PMID: 25559628, PMCID: PMC4435561, DOI: 10.1177/1078345814557513.
- HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort studyMeyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. The Lancet HIV 2014, 1: e77-e84. PMID: 25473651, PMCID: PMC4249702, DOI: 10.1016/s2352-3018(14)70022-0.
- A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the communityDi Paola A, Altice FL, Powell ML, Trestman RL, Springer SA. A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health & Justice 2014, 2: 11. PMID: 25606368, PMCID: PMC4297667, DOI: 10.1186/s40352-014-0011-1.
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the communityDi Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.
- Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison GateMeyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.
- An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexoneVagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Abuse Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.
- Drug Abuse and Alcohol Dependence Among InmatesCepeda J, Springer S. Drug Abuse and Alcohol Dependence Among Inmates. 2014, 1147-1159. DOI: 10.1007/978-1-4614-5690-2_340.
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the communitySpringer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.
- Partner violence and health among HIV-infected jail detaineesMeyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prisoner Health 2013, 9: 124-141. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/ijph-03-2013-0011.
- Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering JailChitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.
- Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite StudyKrishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS And Behavior 2012, 17: 171-180. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.
- Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released PrisonersSpringer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.
- The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic ReviewSpringer SA, Dushaj A, Azar MM. The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic Review. AIDS And Behavior 2012, 16: 2119-2143. PMID: 22644066, PMCID: PMC3481055, DOI: 10.1007/s10461-012-0212-3.
- Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomesSaber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.
- Adherence to HIV Treatment and Care Among Previously Homeless Jail DetaineesChen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL. Adherence to HIV Treatment and Care Among Previously Homeless Jail Detainees. AIDS And Behavior 2011, 17: 2654-2666. PMID: 22065234, PMCID: PMC3325326, DOI: 10.1007/s10461-011-0080-2.
- High rates of depressive symptomatology among injecting drug users in Saskatoon, CanadaSpringer SA. High rates of depressive symptomatology among injecting drug users in Saskatoon, Canada. BMJ Mental Health 2011, 15: 9. PMID: 22044870, DOI: 10.1136/ebmh.2011.100199.
- HIV-Related Research in Correctional Populations: Now is the TimeRich JD, Wohl DA, Beckwith CG, Spaulding AC, Lepp NE, Baillargeon J, Gardner A, Avery A, Altice FL, Springer S, On behalf of the Centers for AIDS Research—Collaboration on HIV in Corrections (CFAR-CHIC) Working Group. HIV-Related Research in Correctional Populations: Now is the Time. Current HIV/AIDS Reports 2011, 8: 288. PMID: 21904902, PMCID: PMC3208731, DOI: 10.1007/s11904-011-0095-3.
- Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential ComponentsSpringer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.
- HIV Treatment in the Criminal Justice System: Critical Knowledge and Intervention GapsMeyer JP, Chen NE, Springer SA. HIV Treatment in the Criminal Justice System: Critical Knowledge and Intervention Gaps. AIDS Research And Treatment 2011, 2011: 680617. PMID: 21776379, PMCID: PMC3137962, DOI: 10.1155/2011/680617.
- Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United StatesChen N, Meyer J, Springer S. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infectious Disease Reports 2011, 3: 6. DOI: 10.4081/idr.2011.2362.
- Substance Abuse, Violence, and HIV in Women: A Literature Review of the SyndemicMeyer JP, Springer SA, Altice FL. Substance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic. Journal Of Women's Health 2011, 20: 991-1006. PMID: 21668380, PMCID: PMC3130513, DOI: 10.1089/jwh.2010.2328.
- Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United StatesChen NE, Meyer JP, Springer SA. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infectious Disease Reports 2011, 3: e6. PMID: 23745166, PMCID: PMC3671603, DOI: 10.4081/idr.2011.e6.
- HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisonersSpringer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American Journal Of Drug And Alcohol Abuse 2010, 37: 12-21. PMID: 21171933, PMCID: PMC3070290, DOI: 10.3109/00952990.2010.540280.
- A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilizationAzar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug And Alcohol Dependence 2010, 112: 178-193. PMID: 20705402, PMCID: PMC2997193, DOI: 10.1016/j.drugalcdep.2010.06.014.
- Neurocognitive Impairment and HIV Risk Factors: A Reciprocal RelationshipAnand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship. AIDS And Behavior 2010, 14: 1213-1226. PMID: 20232242, PMCID: PMC2906682, DOI: 10.1007/s10461-010-9684-1.
- Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine TreatmentSpringer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.
- DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested InterventionsAltice FL, Springer SA. DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. JAMA Internal Medicine 2010, 170: 109-110. PMID: 20065210, PMCID: PMC2825565, DOI: 10.1001/archinternmed.2009.459.
- Commentary on Larney (2010): A call to action—opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid‐dependent prisonersSpringer SA. Commentary on Larney (2010): A call to action—opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid‐dependent prisoners. Addiction 2010, 105: 224-225. PMID: 20078481, PMCID: PMC2825564, DOI: 10.1111/j.1360-0443.2009.02893.x.
- Improving Healthcare for Incarcerated WomenSpringer SA. Improving Healthcare for Incarcerated Women. Journal Of Women's Health 2010, 19: 13-15. PMID: 20088653, PMCID: PMC2828190, DOI: 10.1089/jwh.2009.1786.
- Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapySpringer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.
- Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled TrialMaru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.
- A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. Journal Of Opioid Management 2008, 4: 81-6. PMID: 18557164, PMCID: PMC2476214, DOI: 10.5055/jom.2008.0012.
- Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral TherapyMaru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.
- Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral ResistanceMaru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.
- Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled TrialAltice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.
- Antiretroviral Treatment Regimen Outcomes Among HIV-Infected PrisonersSpringer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.
- Improving the Care for HIV-Infected Prisoners: An Integrated Prison-Release Health ModelSpringer S, Altice F. Improving the Care for HIV-Infected Prisoners: An Integrated Prison-Release Health Model. 2007, 535-555. DOI: 10.1007/978-0-387-71695-4_30.
- Chapter 14 HIV in the Correctional FacilityAltice F, Springer S. Chapter 14 HIV in the Correctional Facility. 2006, 182-216. DOI: 10.1016/b978-0-323-03265-0.50019-1.
- Managing HIV/AIDS in correctional settingsSpringer SA, Altice FL. Managing HIV/AIDS in correctional settings. Current HIV/AIDS Reports 2005, 2: 165-170. PMID: 16343373, DOI: 10.1007/s11904-005-0011-9.
- Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infectionAltice FL, Marinovich A, Khoshnood K, Blankenship KM, Springer SA, Selwyn PA. Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infection. Journal Of Urban Health 2005, 82: 312-326. PMID: 15872190, PMCID: PMC3456574, DOI: 10.1093/jurban/jti055.
- Reply to Babudieri et alAltice F, Springer S, Pesanti E. Reply to Babudieri et al. Clinical Infectious Diseases 2005, 40: 322-323. DOI: 10.1086/426152.
- 18 Management of HIVIAIDS in Correctional SettingsAltice F, Springer S. 18 Management of HIVIAIDS in Correctional Settings. 2005, 449-487. DOI: 10.1016/b978-012465271-2/50021-2.
- Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program ReplicationAltice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.
- Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the CommunitySpringer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.
- Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug usersAltice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health 2003, 80: 416-427. PMID: 12930880, PMCID: PMC3455979, DOI: 10.1093/jurban/jtg053.
- Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic AcidosisSpringer SA, Altice FL. Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis. Clinical Infectious Diseases 2003, 36: e162-e164. PMID: 12802782, DOI: 10.1086/374930.
- A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers.Springer SA, Gastfriend DR. A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. Journal Of Addictive Diseases 1995, 14: 53-66. PMID: 8541360, DOI: 10.1300/J069v14n02_06.
- Gender differences in cerebral perfusion in cocaine abuse: technetium-99m-HMPAO SPECT study of drug-abusing women.Levin JM, Holman BL, Mendelson JH, Teoh SK, Garada B, Johnson KA, Springer S. Gender differences in cerebral perfusion in cocaine abuse: technetium-99m-HMPAO SPECT study of drug-abusing women. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 1994, 35: 1902-9. PMID: 7989967.
- Cocaine effects on pulsatile secretion of ACTH in men.Teoh SK, Sarnyai Z, Mendelson JH, Mello NK, Springer SA, Sholar JW, Wapler M, Kuehnle JC, Gelles H. Cocaine effects on pulsatile secretion of ACTH in men. The Journal Of Pharmacology And Experimental Therapeutics 1994, 270: 1134-8. PMID: 7932162.
Clinical Trials
Conditions | Study Title |
---|---|
Addictive Behaviors; HIV/AIDS; Infectious Diseases | Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures |